← All trials
NCT03680274
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 25, 2018
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 800
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of SherbrookeLead sponsor
- University of TorontoOverall official - principal investigator
- University of SherbrookeReponsible party - principal investigator
- Lotte & John Hecht Memorial FoundationCollaborator
- University of SherbrookeOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.